Better Results For Invega Over Seroquel Could Enhance J&J’s Bottom Line At AstraZeneca’s Expense
This article was originally published in The Pink Sheet Daily
Executive Summary
Invega could cut into Seroquel’s hefty share of “churn” segment of antipsychotic market.